WebDicerna, which was acquired by a leading global healthcare company in December 2024, uses ribonucleic acid interference (RNAi) to develop medicines that silence or turn off the genes that can cause or contribute to disease. WebFeb 21, 2024 · Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented.
Lilly and Dicerna Announce RNAi Licensing and Research …
WebIn 2024, prior to its acquisition, Dicerna was gearing up for commercial manufacturing and needed help to quickly select and implement a scalable technology platform for growth … WebAt Dicerna, we use RNA interference, or RNAi, to create medicines that silence or turn off the genes that cause or contribute to disease. Using our GalXC™ and GalXC-Plus™ technologies , we aim to develop safe, effective, specific and convenient RNAi therapies … At Dicerna, we are developing a pipeline of RNAi therapies designed to improve … Healthy mind and body. We believe progress starts with our people, so we’ll … We are investigating belcesiran (DCR-A1AT) as part of a clinical development … We go right to the source. Genes play a primary role in thousands of diseases. … In October 2024, Dicerna entered into a research collaboration and licensing … Dicerna Pharmaceuticals. 75 Hayden Avenue Lexington, MA 02421. 33 … Dicerna has continued to innovate and is exploring new applications of its RNAi … At Dicerna, we are committed to working with patient communities to understand … At Dicerna Pharmaceuticals, we see drug development as a team endeavor. As … In alignment with Dicerna’ s commitment to scientific innovation and areas of unmet … reading two way tables tes
Dicerna and Novo Nordisk Enter Agreement to Discover and …
WebAug 11, 2024 · Whilst it may not be a huge deal, we thought it was good to see that the Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Independent Director, Marc Kozin, recently bought US$71k worth of stock, for... WebDicerna Pharmaceuticals, Inc. University of Michigan About Senior leader skilled at defining Human Resources strategy and driving change. Extensive global and national experience with increasing... reading tv sale and repair